Startups channel feed – Endpoints News

Startups channel feed

Immetas Therapeutics nabs $11M Series A to narrow their bispecific work targeting inflammation in age-related diseases

5 years ago

Can a magnetic cell therapy replace corneal transplantation? As eight-year journey leads to the clinic, two brothers unveil bold vision

5 years ago

Lava breaks prolonged silence with an $83M Series C and two I/O programs set for the clinic

5 years ago

Versant teams up with Stanford gene editing experts on a $45M next-gen play — marrying CRISPR and AAV to fix sickle cell

5 years ago

Arie Belldegrun and David Chang godfather the $110M launch of a new cell therapy player. And this one is also thinking big

5 years ago

Exclusive: Ginkgo teams with unknown upstart in hunt for Covid-19 antibody

5 years ago

FL56+FL57= infinite possibilities? Flagship's hybrid startup takes machine learning in drug discovery to the next level — and Covid-19 offers a quick test

5 years ago

New targeted therapy approaches win Rain Therapeutics $63M — designed to beat a quick path to approval

5 years ago

A pair of Bay Area biotech upstarts with deep pockets and a shared interest in curative cancer drugs join R&D forces

5 years ago

Driving to the $278M mark on raises, a legendary R&D expert sets his sights on another pivotal goal line

5 years ago

'We want to be everywhere.' Mission Bio raises $70M behind resistance-hunting sequencing platform

5 years ago

Perceptive births its first in-house startup — and it's a China play

5 years ago

RA Capital-backed Aerovate launches with $72.6M to treat PAH with a repurposed cancer med

5 years ago

Versant funds TCR therapy biotech T-knife's $78M+ Series A to boost humanized T cell mice platform

5 years ago

Less than 3 months after launch, the AveXis crew’s Taysha raises $95M Series B. Is an IPO next?

5 years ago

Versant debuts Ridgeline's startup #4, armed with $30M and alternative TCR cell therapies for solid tumors

5 years ago

IgGenix emerges from stealth with $10 million Series A hoping to re-engineer allergic cascade

5 years ago

'Exquisite control': Flagship pulls off $85M rally around Omega Therapeutics' clinical push for epigenetic programming tech

5 years ago

Three years after leaving Biogen, Alpna Seth takes the spotlight with $73M for her neuro startup

5 years ago

A protein engineering platform spawns a new IL-2 player out of Basel, with human trials looming next summer

5 years ago

Successful scientist-investor allies team up again — this time for a stab at rare metabolic disease

5 years ago

Christoph Westphal bags a $170M Fund V, slated to help breed some new biotechs at Longwood

5 years ago

'Missing link': Bayer, Morningside help catapult a new kind of delivery tech to cell and gene therapy

5 years ago

Cullinan Oncology launches new subsidiary focused on collagen-binding cytokine treatment

5 years ago

First page Previous page 50 51 525354 55 56 Next page Last page